Pressure is mounting on pharmaceutical companies as drug development costs soar past $2.23 billion per drug for large firms, timelines stretch 10 to 15 years, and nearly 90% of clinical trials end in failure. At the same time, the demand for faster, more affordable, and effective therapies continues to climb. Artificial intelligence (AI) has emerged as a powerful potential solution, promising to revolutionize how drugs are discovered, developed, and brought to patients.
In this webinar, Sara Mallatt, AlphaSense’s Director of Healthcare Research, will explore with Dr. Paul Agapow, Former Director of Data Science at GSK, how Al is being used to address today’s biggest opportunities and challenges in drug discovery and development, as well as where the field is headed. Drawing on the latest data and expert insights, they will assess how Al is performing against high expectations, what’s working, and what’s not. They will also dissect the competitive arena, covering key players from pharma giants to “TechBios,” and the mergers, acquisitions, and collaborations that are defining the future
You’ll walk away with a clear-eyed view of where Al is delivering real value in drug development, where it still needs to prove itself, and what to watch for next
View Whitepaper